



The most complete service at the highest quality standards

Eurofins stands for a conception of clinical diagnostics entirely focused on excellence, innovation and technological investment. With tens of thousands of clinical diagnostic tests performed every day, we strive to ensure that every patient, wherever he or she lives, is assured access to the most specialized and most innovative techniques for diagnosis, monitoring and therapeutic adjustment. Eurofins clinical diagnostics offers testing services in all medical specialties, from routine testing to esoteric testing including genetic testing.



The commitment of our laboratories: with our logistics expertise and our daily sample collection and delivery network, we guarantee perfect continuity in the provision of care, and the same quality and access to innovation across all the regions that we serve. It is our mission to offer the most innovative tests to the wider population at a cost that is affordable for society.

Oncology by Eurofins Clinical Diagnostics



- Several projects with pharma companies
- Diagnostic tests for major and rare cancers
- From sample pick-up to medical counseling
- Clinical interpretation provided
- Accredited laboratories






Find Eurofins Clinical Diagnostics in your country!

For more information on Eurofins Clinical Diagnostics Services please contact us!

Eurofins GSC LUX
Val Fleuri 23
1526 Luxembourg
Phone: +352 26 18 53 20
Fax: +352 26 18 53 31
CDx@eurofins.com

Stay in touch by following us on social media.

You can find us on:

-  @EurofinsGroup
-  www.facebook.com/EurofinsGroup
-  www.linkedin.com/company/Eurofins

www.eurofins.com

Oncology

Innovating today
for the health of tomorrow

www.eurofins.com

Fighting cancer with early diagnosis



Eurofins clinical diagnostics has a broad portfolio of tests focused on cancer predisposition and cancer risk monitoring. These novel tests have enabled the early diagnosis of cancer for high risk individuals. A clear benefit of these tests is the increased life expectancy thanks to the prompt management of the disease.

Predisposition screening

Germline mutations are at the origin of cancers with an hereditary component. Those mutations affect an oncosuppressor gene and could lead to cancer as a consequence but not always. Genetic tests targeting germline mutations are recommended only to people with a strong family history of cancer. Only 5 to 10% of cancers have an hereditary component.

Risk monitoring

For those individuals that could be at risk of developing cancer, we offer genetic panels to screen for somatic mutations in cancer driver genes. Somatic mutations are spontaneous as opposed to germline mutations described before. These genetic panels are recommended for people with a clear family history of cancer, smokers, people that have been exposed to known carcinogens or to UV light for long periods or that have been under some hormone therapies. The screening needs to be performed periodically.

Diagnostics

Serum biomarkers have been used for many years to help in cancer diagnosis. The alteration of any of the serum markers indicates an organ malfunction which could be caused by cancer. A confirmatory diagnosis by other means will then follow. If cancer diagnosis is confirmed, tumor characterization through biopsy will be the next step. Genetic testing offers molecular tumor profiling which provides a full picture of the clinical situation. Other analyses such as cytogenetics, fluorescence in situ hybridization (FISH) and immunophenotyping which are used in the diagnosis of hematological malignancies are also available at Eurofins.

Increasing life expectancy

Advances in genetics and proteomics allow for a personalized treatment of patients that translates in lower risk of recurrence and so better prognosis. At Eurofins we are committed to contribute to personalized medicine and have invested heavily in new genetic tests to offer the best possible care to patients and increase their life expectancy.

Treatment personalization and monitoring

Depending on the tumor molecular profile, a different treatment will be recommended. The Eurofins pharmacogenetics testing allows understanding patient's drug metabolism and adjusting the treatment dose accordingly. With this dual testing approach, Eurofins delivers the full clinical picture to oncologists that will decide on the treatment for each individual patient. Treatment follow-up with liquid biopsy will allow adjustment if needed. Liquid biopsy follows on cancer driver mutations in tumor cell-free DNA. As the test is non-invasive, i.e. only a blood draw is required; it can be performed periodically without discomfort for the patient.



Prognosis testing

Molecular characterization of tumors or tumor profiling has enabled the creation of a molecular classification that is used for diagnosis and treatment definition but also for patient prognosis. At Eurofins we offer DNA- and RNA-based tests as well as proteomics that combined with the patient's clinical history inform on cancer staging and malignancy level.

Eurofins Clinical Diagnostics helping to fight cancer

